-+ 0.00%
-+ 0.00%
-+ 0.00%

Axsome settles all Sunosi patent litigation, sets generic entry for 2040

PUBT·06/03/2026 11:03:29
Listen to the news
Axsome settles all Sunosi patent litigation, sets generic entry for 2040
  • Axsome Therapeutics settled all U.S. patent litigation tied to SUNOSI following a deal with the last remaining first-to-file generic challenger.
  • The settlement grants five companies the right to launch generic SUNOSI on or after Sep. 1, 2040 with pediatric exclusivity, or Mar. 1, 2040 without it.
  • No other SUNOSI patent cases remain pending; the agreement will be submitted to the FTC and DOJ for review.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606030700PRIMZONEFULLFEED9731085) on June 03, 2026, and is solely responsible for the information contained therein.